Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Olaptesed pegol - NOXXON Pharma

Drug Profile

Olaptesed pegol - NOXXON Pharma

Alternative Names: Anti-CXCL12/SDF-1 Spiegelmer®; NOX-A12

Latest Information Update: 12 Nov 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator NOXXON Pharma AG
  • Developer NOXXON Pharma AG; Unknown
  • Class Antineoplastics; Eye disorder therapies; Oligonucleotides; Polyethylene glycols
  • Mechanism of Action Angiotensin inhibitors; Chemokine CXCL12 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Glioblastoma
  • New Molecular Entity Yes
  • Available For Licensing Yes - Cancer

Highest Development Phases

  • Phase II Chronic lymphocytic leukaemia; Multiple myeloma
  • Phase I/II Colorectal cancer; Glioblastoma; Pancreatic cancer
  • Preclinical Unspecified
  • Discontinued Diabetic retinopathy

Most Recent Events

  • 12 Nov 2019 Olaptesed pegol - NOXXON Pharma is available for licensing as of 12 Nov 2019. https://www.noxxon.com/index.php?option=com_content&view=article&id=20&Itemid=477 9277781
  • 24 Oct 2019 Noxxon files a CTA application with Federal Institute for Drugs and Medical Devices (BfArM) for initiation of a phase I/II trial in Brain cancer
  • 24 Oct 2019 NOXXON plans a phase I/II trial for Brain cancer in
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top